Use of G007-LK for Osteogenic Differentiation and Bone Regeneration
Summary
The USPTO has published patent application US20260085289A1, detailing the use of a compound known as G007-LK. The application, filed by the Hospital of Stomatology, Guangzhou Medical University, describes G007-LK's potential to promote osteogenic differentiation of dental stem cells and aid in bone tissue regeneration.
What changed
This document is a published patent application (US20260085289A1) from the USPTO, detailing the use of G007-LK for promoting osteogenic differentiation of dental mesenchymal stem cells and bone tissue regeneration. The application, filed by the Hospital of Stomatology, Guangzhou Medical University, presents in vitro and in vivo experimental data suggesting G007-LK has osteoinductive properties and could be applied as an osteogenic drug for bone regeneration.
This is a patent application, not a final rule or guidance. It signifies a disclosure of an invention and does not impose immediate compliance obligations on regulated entities. However, it indicates potential future developments in the pharmaceutical and medical device sectors related to bone regeneration therapies. Companies involved in regenerative medicine, stem cell research, or bone graft materials should monitor the progression of this patent and related technologies.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
USE OF G007-LK IN PROMOTING OSTEOGENIC DIFFERENTIATION OF DENTAL MESENCHYMAL STEM CELLS
Application US20260085289A1 Kind: A1 Mar 26, 2026
Assignee
HOSPITAL OF STOMATOLOGY, GUANGZHOU MEDICAL UNIVERSITY
Inventors
Jianwen LI, Yunyang LI, Yunqin YAN, Xi XIANG, Lingling OU, Sujuan ZENG, Chaoyang MA, Bo PENG, Xuguang GAO, Janak lal PATHAK
Abstract
Disclosed is a use of G007-LK in promoting osteogenic differentiation of dental mesenchymal stem cells and bone tissue regeneration. In vitro experiments of the present application show that G007-LK has the ability to induce SHED to form mineralized nodules and promote osteogenic differentiation; in vivo experiments show that G007-LK pretreatment of SHED for 7 days combined with Geistlich Bio-Oss® collagen bone scaffold can enhance the in vivo osteogenic effect of SHED and promote the subcutaneous ectopic osteogenesis of nude mice, indicating that G007-LK has good osteoinductivity and is a potential osteogenic drug. Therefore, G007-LK can promote osteogenic differentiation of dental mesenchymal stem cells and be applied to bone tissue regeneration.
CPC Classifications
C12N 5/0654 C12N 5/0018 C12N 2501/999 C12N 2506/1361
Filing Date
2025-11-24
Application No.
19399509
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.